Wilson Sonsini advised Iambic Therapeutics, a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, in connection with the company’s $150 million initial public offering (IPO). Iambic issued 9,375,000 shares of its common stock at a public offering price of $16 per share, with a 30-day option for the underwriters to purchase up to an additional 1,406,250 shares. Iambic’s common stock began trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker symbol “IAM.”

J.P. Morgan, Jefferies, BofA Securities, and Citigroup acted as joint book-running managers for the offering.

The Wilson Sonsini team that advised Iambic on the transaction was led by Zachary Myers, Christina Poulsen, Victor Nilsson, Megan Schilling, Patrick Schultheis, Deborah Smith, and Eva Yin. The team also included:

Corporate
Bridget Balisy
Trevor Dorne
Conor Guest
Zach Shen
Aletha Tarn
Alex Weber

Patents and Innovations
Grant Margulieux

Employee Benefits and Compensation
Brett Condie
Emma Wilcox

For more information, please see Iambic’s news release.